-
Dr Galsky on Durvalumab's FDA Approval in Muscle-Invasive Bladder Cancer
03 Apr 2025 20:47 GMT
… combined with gemcitabine and cisplatin as neoadjuvant treatment, followed by … population in the NIAGARA trial.2 According to Matt … urothelial cancer,” explained Galsky, medical oncologist at the Icahn … delved into the recent FDA approval of durvalumab in …
-
Differential response of low- and high-grade intermediate-risk non-muscle-invasive bladder cancer to bacillus Calmette-Guérin and gemcitabine-docetaxel therapy.
03 Apr 2025 16:42 GMT
Sequential intravesical gemcitabine/docetaxel (Gem/Doce … validate these findings and refine treatment strategies.
Urologic oncology. 2025 … of Urology, Icahn School of Medicine at Mount Sinai, New … Urology, Icahn School of Medicine at Mount Sinai, New …
-
Oncology Drugs Approved by the FDA in March 2025
01 Apr 2025 19:21 GMT
… drugs included treatments for … FDA approved neoadjuvant therapy with durvalumab (Imfinzi) for use with gemcitabine … FDA approves new prostate cancer imaging agent Gozellix. News release. Telix Pharmaceuticals … trial of neoadjuvant durvalumab plus chemotherapy …
-
OncLive’s FDA Approval Report: The Regulatory Rundown for March 2025
03 Apr 2025 02:31 GMT
… . “When considering similar drugs [to cabozantinib] in … 3 NIAGARA trial (NCT03732677) supported the FDA’s … paired with gemcitabine and cisplatin as neoadjuvant treatment, followed by … and Harvard Medical School, detailed clinical trials investigating the …
-
Theriva Biologics announces positive outcomes from second meeting of the IDMC for VIRAGE phase 2b trial of VCN─01 in combo with chemotherapy for metastatic PDAC
02 Apr 2025 12:46 GMT
… population and the medications being studied.
The … controlled, multicenter clinical trial in patients with histologically … VCN-01 treatment arms, patients receive gemcitabine/ … European Union Drug Regulating Authorities Clinical Trials Database (EudraCT …
-
Compass touts ABL Bio-partnered bispecific after pivotal trial success in biliary tract cancer
02 Apr 2025 01:57 GMT
… move upstream into frontline treatment. A trial led by MD Anderson … testing tovecimig in combination with gemcitabine, cisplatin and checkpoint inhibitor … —the target for Compass’ drug—are left with FOLFOX, … fill that gap. The biotech estimates about 23,000 BTC …
-
Dive Into March 2025 FDA Approvals Across Cancer Subtypes
01 Apr 2025 21:46 GMT
… U.S. Food and Drug Administration (FDA) granted approval to several therapeutic … , the FDA green lit neoadjuvant treatment with Imfinzi (durvalumab) plus gemcitabine and cisplatin … the multicenter, open-label PSMAfore trial, which evaluated 468 patients with …
-
FDA clears AstraZeneca’s blockbuster Imfinzi for muscle-invasive bladder cancer treatment
01 Apr 2025 18:05 GMT
… Drug Administration (FDA) has approved AstraZeneca’s Imfinzi (durvalumab) in combination with gemcitabine … .
Moreover, according to the trial results, the drug also reduced the risk … a significant need for new treatment options that improve patient outcomes …
-
RenovoRx Reports Initial Revenues from RenovoCath® Commercialization, and Provides Update on Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial
01 Apr 2025 12:47 GMT
… for the trial. RenovoRx is … Drug Administration (FDA)-cleared local drug delivery device, targeting high unmet medical … gemcitabine, and the RenovoCath device is currently being evaluated for the treatment … property development, clinical trials, our therapy …
-
AstraZeneca’s Imfinzi regimen approved by FDA to treat muscle-invasive bladder cancer
01 Apr 2025 11:33 GMT
… by the US Food and Drug Administration (FDA) to treat adults with … combination with gemcitabine and cisplatin chemotherapy as a neoadjuvant treatment prior to … from the phase 3 NIAGARA trial.
The Imfinzi regimen demonstrated a …
About
© 1995-2025